Overview

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

CREST-KT is a single-center, double-blinded, randomized trial of dapagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to dapagliflozin 10mg versus placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Duke University

Treatments:

2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin